Pharmacokinetics and bioequivalence evaluation of lenalidomide in Chinese patients with multiple myeloma

Chin Med J (Engl). 2021 Sep 9;135(2):250-252. doi: 10.1097/CM9.0000000000001695.
No abstract available

Publication types

  • Letter

MeSH terms

  • China
  • Humans
  • Lenalidomide / therapeutic use
  • Multiple Myeloma* / drug therapy
  • Thalidomide
  • Therapeutic Equivalency

Substances

  • Thalidomide
  • Lenalidomide